University of Rochester, New York, NY, USA.
Clin Lymphoma Myeloma Leuk. 2010 Oct;10(5):E43-6. doi: 10.3816/CLML.2010.n.074.
Plasmablastic lymphoma (PBL) is an aggressive lymphoma classified by the World Health Organization as a subtype of diffuse large B-cell lymphoma that shares many morphologic and immunophenotypic features with multiple myeloma. It is extremely rare in immunocompetent patients. Because of the small number of patients reported, this rare lymphoma remains a poorly characterized and understood entity with presently no standard recommendations regarding the optimal treatment. Herein, we report a dramatic clinical response coupled with tumor lysis syndrome to a bortezomib-based treatment in an HIV-negative patient with refractory plasmablastic lymphoma.
浆母细胞淋巴瘤（PBL）是一种侵袭性淋巴瘤，世界卫生组织将其归类为弥漫性大 B 细胞淋巴瘤的一个亚型，与多发性骨髓瘤具有许多形态学和免疫表型特征。它在免疫功能正常的患者中极为罕见。由于报告的患者数量较少，这种罕见的淋巴瘤仍然是一个特征和了解甚少的实体，目前对于最佳治疗方法尚无标准建议。在此，我们报告了一例 HIV 阴性、难治性浆母细胞淋巴瘤患者接受硼替佐米为基础的治疗后出现戏剧性的临床缓解和肿瘤溶解综合征。
